Chapter 17 - Vaccine-Based Immunotherapy for Pancreatic and Colon Cancers
Document Type
Book Chapter
Publication Title
Immune Therapy for Pancreatic and Colon Cancers
Abstract
Gastrointestinal (GI) cancers comprise about a quarter of all cancer cases, and the incidence of these cancers has consistently risen in recent years. Common risk factors for GI cancers include smoking, alcohol consumption, obesity, and infections. Immuno-checkpoint inhibitors like cytotoxic T-lymphocyte-associated antigen four antibodies show promise, however only benefitting a fraction of patients prompted to explore additional strategies for cancer immunotherapy. Cancer vaccines, originally designed for infectious diseases, stimulate immune responses, offering potential in cancer treatment, particularly for cancers like colorectal and pancreatic cancers. Several vaccines are tested and currently in testing using both preclinical experiments and clinical trials. Further research is needed for sophisticated vaccine technology, and the development of precision-based vaccines holds promise for preventing and treating GI cancers. Cancer vaccine research is progressing rapidly, addressing limitations and offering hope for precise vaccine development.
DOI
10.1016/B978-0-443-24742-2.00023-X
Publication Date
1-17-2025
ISBN
978-0-443-24742-2
Publisher
Elsevier/Academic Press
Recommended Citation
Dhother B, Rajan M, Kurri A, Mohammed A, Dudhia A, Cheng F, Basha R. Chapter 17 - Vaccine-Based Immunotherapy for Pancreatic and Colon Cancers. Immune Therapy for Pancreatic and Colon Cancers. 2025; . doi: 10.1016/B978-0-443-24742-2.00023-X.
